Sanofi announced today the successful completion of its acquisition of Synthorx, Inc. (“Synthorx”) for $68 per share in cash. “The acquisition of Synthorx perfectly aligns with our R&D strategy, enhancing our position as an emerging leader in the area of oncology and immunology,” says Paul Hudson, Chief Executive Officer, Sanofi. “We gain access to both great scientists and science with THOR-707, an engineered not-alpha IL-2 for the treatment of solid tumors which induces strong immunological responses in vivo, additional intriguing pre-clinical assets, and a powerful platform that complements our ongoing oncology and immunology research.”
Read the full article: Sanofi Completes Acquisition of Synthorx, Inc. //
Source: https://www.globenewswire.com/news-release/2020/01/23/1974331/0/en/Sanofi-Sanofi-Completes-Acquisition-of-Synthorx-Inc.html